My ePortfolio Register   

Comprehensive sequencing programme shows promise of precision medicine for advanced cancer

The average metastatic cancer has more genetic mutations than are seen in early stage tumours, a new study finds.

What that means: To make precision medicine a reality in cancer care, you need a real-time, comprehensive approach that looks at the metastatic tumours and sequences to a level of detail beyond most commercial tests.

In one of the largest and most comprehensive efforts to examine the genetic and molecular landscape of advanced cancer, researchers at the University of Michigan Comprehensive Cancer Center sequenced the DNA and RNA of 500 patients with metastatic cancer.

The results are published in Nature.

Three things make this analysis unique:

  • Researchers obtained fresh biopsies for most patients, extracting samples from the metastatic tumours, rather than the primary tumour.
  • They sequenced both DNA and RNA.
  • They compared the cancerous tissue to the patient's normal DNA.

"This is a more comprehensive approach than most commercially available clinical sequencing programmes. Our results suggest value on several levels to this more detailed approach," says senior study author Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology.

The data reflects the first 500 patients with solid tumours to enroll in the Michigan Oncology Sequencing Program, a research protocol that began in 2010, sequencing the DNA and RNA of metastatic cancers and normal tissue to identify alterations that could help drive treatment.

The program includes a precision medicine tumour board in which experts discuss each case. Mi-ONCOSEQ was among the first comprehensive clinical sequencing programmes offered for cancer patients.

The patients represented in the Nature paper spanned more than 30 types of cancer, with metastases in 22 different organs.

It includes only adults with solid tumours, although Mi-ONCOSEQ is available to patients with blood cancers and to children.

Biopsy the metastasis, not archived tumour

Researchers found a significant increase in the number and type of mutations between patients' metastatic cancer and primary cancer.

Nearly every case of metastatic cancer had more mutations, they found.

This likely reflects that metastatic cancers are more aggressive: they've had more time to develop additional mutations, and treatments designed to kill the cancer have caused more mutations.

"Our findings emphasise the importance of getting a fresh biopsy of the metastatic tumour," Chinnaiyan says.

"Tumours are evolving as part of metastasis and under therapy. We need to biopsy the metastatic tumours and then suggest therapies, rather than using archival tissue from the primary tumour."

RNA sequencing reveals more targets

The other key component is sequencing the RNA as well as the DNA.

This more extensive approach revealed a host of molecular factors that play a role in the tumour microenvironment, fostering and allowing the cancer to continue to grow, spread or evade treatment.

Generally, most clinical sequencing efforts focus on DNA sequencing only.

While DNA sequencing reveals genetic alterations involved in metastatic cancer, researchers found RNA sequencing shed light on the underlying mechanisms that either turn on cancer-causing genes or turn off the genes meant to stop cancer.

Their findings could help identify potential targets for treatment.

In addition, by looking at RNA, researchers could examine the immune cells in the tumour microenvironment, which offered clues to why immunotherapy might work for some patients but not for others.

"Understanding the immune microenvironment - the types of cells infiltrating the tumour and what they are expressing - is important. It gives us a picture of the immuno-phenotype. Our hypothesis is that we could use this to help determine who is likely to respond to immunotherapy," Chinnaiyan says, noting that more research is needed in this area.

Another key finding is that metastatic tumours exhibited one of two mutually exclusive signatures.

One version was highly proliferative, meaning it multiplied aggressively. In the other version, cells lost their differentiation, a state called epithelial to mesenchymal transition.

"Not all metastases are the same. Different pathways are driving them to be quite different - highly proliferative versus those that are differentiating more. This mutually exclusive aspect was a striking finding that could guide us in developing new types of therapies," Chinnaiyan says.

Inherited mutations uncovered

Another striking finding was that 12 percent of the metastatic cancer patients harbored an inherited mutation.

This is roughly quadruple what might be expected among all cancer patients. These mutations were identified by comparing the tumour DNA to the normal DNA.

About three-quarters of these mutations were related to the process of DNA repair, which several existing therapies are designed to target.

"There is a high percentage of inherited mutations in metastatic cancer. Once these mutations are identified, it's possible others in the family may also carry that gene and be at higher risk of cancer," Chinnaiyan says.

Family members might seek genetic counselling or additional screening, if appropriate. Patients in Mi-ONCOSEQ received genetic counselling, which was also extended to their families in cases of inherited mutation.

The researchers are currently analysing patient outcomes from this initial group. Preliminary data presented earlier this year at the American Society of Clinical Oncology annual meeting suggested that three-quarters of patients whose tumours were sequenced had an "actionable mutation," meaning treatments exist to target that specific aberration.

In total, nearly 2,300 patients have enrolled in Mi-ONCOSEQ to date.

Source: Michigan Medicine | University of Michigan



Please click on the 'New Comment' link to the left to add a new comment, or alternatively click any 'Add Comment' link next to any existing post to respond. The views expressed here are not those of ecancer. For more information please view our Privacy Policy.

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence